Department of Vascular Surgery, Leiden University Medical Center, Leiden, The Netherlands.
J Vasc Surg. 2010 Feb;51(2):360-71.e1. doi: 10.1016/j.jvs.2009.08.051.
Lower extremity arterial revascularization (LEAR) is the gold-standard for critical lower limb ischemia (CLI). The goal of this study was twofold. First, we evaluated the long-term functional status of patients undergoing primary LEAR for CLI. Second, prognostic factors of long-term functional status and survival after primary LEAR for CLI were assessed.
All primary LEAR procedures were analyzed. Patients were stratified by preoperative functional status: ambulatory (group I) vs nonambulatory (group II). Patients were followed-up after 3 and 6 years. Adverse events (AEs) were categorized according to predefined standards: minor, surgical, failed revascularization, and systemic. Associated patient demographic/clinical data were analyzed using univariate and multivariate methods.
There were 106 LEAR patients (group I: n = 42, 40% vs group II: n = 64, 60%). Group II patients were significantly older (75 vs 62 years; P = .00), were classified ASA 3-4 more frequently (78% vs 52%; P < .02), had more cardiac disease (n = 42, 66% vs n = 10, 24%; P = .00), renal disease (n = 26, 41% vs n = 7, 17%; P = .00), diabetes (n = 36, 56% vs n = 8, 19%; P = .00), hypertension (n = 47, 73% vs n = 13, 31%; P = .00) and severe CLI (n = 42, 66% vs n = 18, 38%; P < .01). Group II patients had a higher incidence of death (65.6% vs 14.3%; P = .00), minor AEs (n = 38, 26% vs n = 10, 22%; P = .00), surgical AEs (n = 48, 33% vs n = 12, 26%; P < .02) and systemic AEs (n = 24, 86% vs n = 4, 9%; P < .02). Also more unplanned reinterventions occurred in group II (n = 148, 76% vs n = 47, 24%; P = .00). Nonambulatory status was a multivariate independent predictor of nonambulatory status after LEAR during 6 years follow-up (odds ration [OR[: 21.47; 95% confidence interval [CI]: 2.76-166.77; P = .00). Pulmonary disease (OR: 7.49; 95% CI: 2.17-25.80; P = .00), not prescribing beta-blockers (OR: 4.67; 95% CI: 1.28-17.03; P < .02), nonambulatory status (OR: 22.99; 95% CI: 6.27-84.24; P = .00), and systemic AEs (OR: 9.66; 95% CI: 1.84-50.57; P < .01) were independent predictors of death. Functional status was not improved in group II after long-term follow-up.
Nonambulatory patients suffer from extensive comorbid conditions. They are accompanied with an increased occurrence of AEs, unplanned reinterventions, and poor long-term survival rates. Successful LEAR did not improve their functional status after 6 years. This emphasizes that attempts for limb salvage must be carefully considered in these patients.
下肢动脉血运重建(LEAR)是治疗严重下肢缺血(CLI)的金标准。本研究的目的有两个。首先,我们评估了 CLI 患者接受原发性 LEAR 的长期功能状态。其次,评估了原发性 LEAR 后长期功能状态和生存的预后因素。
分析了所有原发性 LEAR 手术。根据术前功能状态对患者进行分层:可走动(组 I)与不可走动(组 II)。术后 3 年和 6 年进行随访。根据预先设定的标准对不良事件(AE)进行分类:轻微、手术、血运重建失败和全身性。使用单变量和多变量方法分析相关患者的人口统计学/临床数据。
共有 106 例 LEAR 患者(组 I:n = 42,40% vs 组 II:n = 64,60%)。组 II 患者年龄明显较大(75 岁 vs 62 岁;P =.00),ASA 分级 3-4 更为常见(78% vs 52%;P <.02),心脏病(n = 42,66% vs n = 10,24%;P =.00)、肾脏疾病(n = 26,41% vs n = 7,17%;P =.00)、糖尿病(n = 36,56% vs n = 8,19%;P =.00)、高血压(n = 47,73% vs n = 13,31%;P =.00)和严重 CLI(n = 42,66% vs n = 18,38%;P <.01)更为常见。组 II 患者的死亡率(65.6% vs 14.3%;P =.00)、轻微 AE(n = 38,26% vs n = 10,22%;P =.00)、手术 AE(n = 48,33% vs n = 12,26%;P <.02)和全身性 AE(n = 24,86% vs n = 4,9%;P <.02)的发生率更高。组 II 还发生了更多的计划外再介入(n = 148,76% vs n = 47,24%;P =.00)。非走动状态是 LEAR 后 6 年随访中不能走动状态的独立预测因素(优势比[OR]:21.47;95%置信区间[CI]:2.76-166.77;P =.00)。肺部疾病(OR:7.49;95% CI:2.17-25.80;P =.00)、未开β受体阻滞剂(OR:4.67;95% CI:1.28-17.03;P <.02)、非走动状态(OR:22.99;95% CI:6.27-84.24;P =.00)和全身性 AE(OR:9.66;95% CI:1.84-50.57;P <.01)是死亡的独立预测因素。组 II 患者在长期随访后功能状态没有改善。
不能走动的患者患有广泛的合并症。他们发生 AE、计划外再介入和长期生存率低的情况更为常见。原发性 LEAR 成功并不能改善他们 6 年后的功能状态。这强调了在这些患者中必须谨慎考虑保肢治疗的尝试。